# Trans-Resveratrol (Micronized) - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Micronized polyphenol that allosterically activates SIRT1 deacetylation and stimulates AMPK, replicating key longevity pathways of caloric restriction to reduce liver fat, enhance memory, and improve vascular compliance.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **90/100**
- **Evidence Quality Tier**: **silver**
- **Human Clinical Evidence Strength**: 91/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 91/100 (Higher is safer)
- **Time Burden**: ~1 minutes/day
- **Estimated Monthly Cost**: moderate
- **Adherence Friction**: 2/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
Cell Metabolism and Journal of Neuroscience human RCTs prove AMPK/SIRT1 activation, intrahepatic fat reduction, and enhanced hippocampal functional connectivity; micronization and dietary fat co-administration overcome historic bioavailability limitations.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Heart Health & Endothelial Function**: **88/100** [Rank #13 of 133 in Heart] - Effect: Strong (Activates eNOS, enhances flow-mediated dilation, and reduces oxidized LDL)
    - Mechanism: Directly upregulates endothelial nitric oxide synthase (eNOS) transcription and deacetylates eNOS via SIRT1, improving arterial elasticity and lowering peripheral vascular resistance.
- **Brain Longevity & Neuroprotection**: **91/100** [Rank #14 of 141 in Brain] - Effect: Strong (Enhances hippocampal functional connectivity, delayed recall memory, and cerebral perfusion)
    - Mechanism: Enhances resting-state functional connectivity between the hippocampus and frontal/parietal neocortex while improving cerebral glucose metabolism and neurovascular coupling.
- **Metabolic Flexibility & Glycemic Control**: **90/100** [Rank #12 of 129 in Metabolic] - Effect: Strong (Mimics caloric restriction, activates AMPK, reduces intrahepatic fat by >12%)
    - Mechanism: Inhibits phosphodiesterase 4 (PDE4), elevating intracellular cAMP and driving Epac1-dependent AMPK phosphorylation
- **Cancer Defense & DNA Repair**: **82/100** [Rank #5 of 120 in Cancer Defense] - Effect: Moderate to Strong (Multi-target chemopreventive, suppresses NF-kB, COX-2, and induces apoptosis in malignant cells)
    - Mechanism: Suppresses NF-kB, downregulates cyclooxygenase-2 (COX-2), and inhibits angiogenesis through VEGF reduction, showing broad chemopreventive properties.
- **Endocrine & Anabolic Balance**: **72/100** [Rank #21 of 120 in Endocrine] - Effect: Mild (Optimizes testicular microcirculation and protects against oxidative stress in Leydig cells)
    - Mechanism: Protects Leydig cell membranes from lipid peroxidation and sustains optimal testicular microvascular perfusion.
- **Chronic Inflammation Reduction**: **90/100** [Rank #6 of 126 in Inflammation] - Effect: Strong (Suppresses systemic inflammatory cytokines, TNF-alpha, IL-6, and vascular adhesion molecules)
    - Mechanism: Deacetylates the p65 subunit of NF-kB, disabling its ability to bind DNA and drastically reducing transcription of inflammatory cytokines and vascular adhesion molecules.
- **Bone Density & Connective Matrix**: **78/100** [Rank #24 of 142 in Bone Matrix] - Effect: Moderate (Stimulates osteoblast differentiation through Wnt/beta-catenin and SIRT1 deacetylation)
    - Mechanism: Promotes mesenchymal stem cell differentiation toward the osteogenic lineage over the adipogenic lineage through SIRT1 and Runx2 activation.
- **Cellular Longevity & Autophagy**: **94/100** [Rank #11 of 131 in Cellular] - Effect: Massive (Canonical allosteric SIRT1 activator mimicking caloric restriction-induced longevity signaling)
    - Mechanism: Allosterically binds SIRT1, accelerating deacetylation of downstream longevity targets including PGC-1alpha, FOXO1/3a, and p53, thereby orchestrating mitochondrial biogenesis and autophagic clearance.

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: Refer to individualized clinical assessment
- **Recommended Timing**: Consistent daily schedule
- **Administration Type**: Behavioral / Compound
- **Recommended Biomarkers to Monitor**: energy, focus, metabolic_health, bone_density, heart_health, testosterone

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: Active bleeding disorders or concurrent high-dose anticoagulant therapy (resveratrol exhibits mild antiplatelet activity), Scheduled surgery within 2 weeks
- **Safety Profile**: High Margin - Mild loose stools or abdominal cramps at doses exceeding 1,500 mg/day; Mild nausea on an empty stomach

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Effects of Resveratrol on Memory Performance, Hippocampal Connectivity and Glucose Metabolism in Healthy Older Adults** [PMID: 24899709]
   - Link: https://pubmed.ncbi.nlm.nih.gov/24899709/
2. **Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism in obese humans** [PMID: 22055504]
   - Link: https://pubmed.ncbi.nlm.nih.gov/22055504/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Trans-Resveratrol (Micronized) on LongevityReviews](https://longevityreviews.org/modalities/resveratrol-micronized)
- **Last Evidence Calibration**: 2026-09-09
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.